Clinical utility of gene-expression signatures in early stage breast cancer
Top Cited Papers
- 31 May 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 14 (10), 595-610
- https://doi.org/10.1038/nrclinonc.2017.74
Abstract
Breast cancer is a heterogeneous disease, with different subtypes having a distinct biological, molecular, and clinical course. Assessments of standard clinical and pathological features have traditionally been used to determine the use of adjuvant systemic therapy in patients with early stage breast cancer; however, the ability to identify those who will benefit from adjuvant chemotherapy remains a challenge, leading to the overtreatment of some patients. Advances in molecular medicine have substantially improved the accuracy of gene-expression profiling of breast tumours, resulting in improvements in the ability to predict a patient's risk of breast cancer recurrence and likely response to endocrine therapy and/or chemotherapy. These genomic assays, several of which are commercially available, have aided physicians in tailoring treatment decisions for patients at the individual level. Herein, we describe the available data on the clinical validity of the most widely available assays in patients with early stage breast cancer, with a focus on the development, validation, and clinical application of these assays, in addition to the anticipated outcomes of ongoing prospective trials. We also review data from comparative studies of these assays and from cost-effectiveness analyses relating to their clinical use.Keywords
This publication has 105 references indexed in Scilit:
- Multigene assays and molecular markers in breast cancer: systematic review of health economic analysesBreast Cancer Research and Treatment, 2013
- A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyInternational Journal of Cancer, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2011
- Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trialBritish Journal of Cancer, 2011
- Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancerEuropean Journal Of Cancer, 2010
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancerCancer, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002